BETHESDA, Md., Oct. 17, 2016 -- Condor Hospitality Trust, Inc. (NASDAQ:CDOR), a hotel-focused real estate investment trust (REIT) headquartered and incorporated in the state of Maryland, today announced the closing on the sale of a legacy asset, the 60-room Comfort Inn located at 210 Cavalry Drive, Glasgow, KY 42141 for $2.4 million. The net proceeds from the sale will be used for general corporate purposes and for future acquisitions of hotels that meet the Company’s new investment strategy.
“With the closing of the sale of this hotel, Condor has now sold year-to-date 16 legacy hotels generating $37.0 million in gross proceeds,” said Bill Blackham, Condor’s Chief Executive Officer. “We expect to sell at least 21 legacy hotels this year with the net sales proceeds expected to be reinvested into higher quality, select-service lodging assets such as the downtown Atlanta Aloft acquired in August and the recently announced purchase contract to acquire the Leawood, KS Aloft. The Company currently has signed contracts to sell 7 additional legacy hotels although there can be no guarantee that all of these transactions will actually close,” Mr. Blackham continued.
About Condor Hospitality Trust, Inc.
Condor Hospitality Trust, Inc. (NASDAQ:CDOR), is a self-administered real estate investment trust incorporated in the state of Maryland that specializes in the investment and ownership of upper midscale and upscale, premium-branded select-service, extended stay and limited-service hotels. The company currently owns 27 hotels in 14 states. Condor’s hotels are franchised by a number of the industry’s most well-regarded brand families including Hilton, Marriott, Starwood, InterContinental Hotels Group, Choice, and Wyndham. For more information or to make a hotel reservation, visit www.condorhospitality.com.
Certain matters within this press release are discussed using forward-looking language as specified in the Private Securities Litigation Reform Act of 1995, and, as such, may involve known and unknown risks, uncertainties and other factors that may cause the actual results or performance to differ from those projected in the forward-looking statement. These risks are discussed in the company’s filings with the Securities and Exchange Commission.
Contact: Jonathan J. Gantt Chief Financial Officer & Senior Vice President [email protected] (301) 861-3305


JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Italy Fines Apple €98.6 Million Over App Store Dominance
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



